Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

• Published in: Nature communications Vol. 12; no. 1; pp. 1967 - 10
• Main Authors: Jagannathan, Prasanna, Andrews, Jason R., Bonilla, Hector, Hedlin, Haley, Jacobson, Karen B., Balasubramanian, Vidhya, Purington, Natasha, Kamble, Savita, de Vries, Christiaan R., Quintero, Orlando, Feng, Kent, Ley, Catherine, Winslow, Dean, Newberry, Jennifer, Edwards, Karlie, Hislop, Colin, Choong, Ingrid, Maldonado, Yvonne, Glenn, Jeffrey, Bhatt, Ami, Blish, Catherine, Wang, Taia, Khosla, Chaitan, Pinsky, Benjamin A., Desai, Manisha, Parsonnet, Julie, Singh, Upinder
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2779/777; 692/699/255/2514; Adult; Aged; Antiviral Agents - administration & dosage; Confidence intervals; Coronaviruses; COVID-19; COVID-19 - drug therapy; COVID-19 - virology; Female; Humanities and Social Sciences; Humans; Injections, Subcutaneous; Interferon; Interleukins - administration & dosage; Male; Middle Aged; multidisciplinary; Outpatients; Placebos; Polyethylene Glycols - administration & dosage; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; Single-Blind Method; Transaminase; Treatment Failure; Viral diseases; Virus Shedding - drug effects; Young Adult

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneo...